Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness.

Kari V, Mansour WY, Raul SK, Baumgart SJ, Mund A, Grade M, Sirma H, Simon R, Will H, Dobbelstein M, Dikomey E, Johnsen SA.

EMBO Rep. 2018 Oct;19(10). pii: e46783. doi: 10.15252/embr.201846783. No abstract available.

2.

Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness.

Kari V, Mansour WY, Raul SK, Baumgart SJ, Mund A, Grade M, Sirma H, Simon R, Will H, Dobbelstein M, Dikomey E, Johnsen SA.

EMBO Rep. 2016 Nov;17(11):1609-1623. Epub 2016 Sep 5. Erratum in: EMBO Rep. 2018 Oct;19(10):.

3.

Prevalence of chromosomal rearrangements involving non-ETS genes in prostate cancer.

Kluth M, Galal R, Krohn A, Weischenfeldt J, Tsourlakis C, Paustian L, Ahrary R, Ahmed M, Scherzai S, Meyer A, Sirma H, Korbel J, Sauter G, Schlomm T, Simon R, Minner S.

Int J Oncol. 2015 Apr;46(4):1637-42. doi: 10.3892/ijo.2015.2855. Epub 2015 Jan 27.

PMID:
25625310
4.

More on hepatitis B virus rtI233V mutation and resistance to adefovir.

Sirma H, Schildgen O.

N Engl J Med. 2014 Jul 31;371(5):482-3. doi: 10.1056/NEJMc1406607. No abstract available.

PMID:
25075852
5.

Matrix conditions and KLF2-dependent induction of heme oxygenase-1 modulate inhibition of HCV replication by fluvastatin.

Wuestenberg A, Kah J, Singethan K, Sirma H, Keller AD, Rosal SR, Schrader J, Loscher C, Volz T, Bartenschlager R, Lohmann V, Protzer U, Dandri M, Lohse AW, Tiegs G, Sass G.

PLoS One. 2014 May 6;9(5):e96533. doi: 10.1371/journal.pone.0096533. eCollection 2014.

6.

Heterogeneity and chronology of PTEN deletion and ERG fusion in prostate cancer.

Krohn A, Freudenthaler F, Harasimowicz S, Kluth M, Fuchs S, Burkhardt L, Stahl P, C Tsourlakis M, Bauer M, Tennstedt P, Graefen M, Steurer S, Sirma H, Sauter G, Schlomm T, Simon R, Minner S.

Mod Pathol. 2014 Dec;27(12):1612-20. doi: 10.1038/modpathol.2014.70. Epub 2014 Apr 25.

7.

High RNA-binding motif protein 3 expression is an independent prognostic marker in operated prostate cancer and tightly linked to ERG activation and PTEN deletions.

Grupp K, Wilking J, Prien K, Hube-Magg C, Sirma H, Simon R, Steurer S, Budäus L, Haese A, Izbicki J, Sauter G, Minner S, Schlomm T, Tsourlakis MC.

Eur J Cancer. 2014 Mar;50(4):852-61. doi: 10.1016/j.ejca.2013.12.003. Epub 2013 Dec 28.

PMID:
24380696
8.

βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.

Tsourlakis MC, Weigand P, Grupp K, Kluth M, Steurer S, Schlomm T, Graefen M, Huland H, Salomon G, Steuber T, Wilczak W, Sirma H, Simon R, Sauter G, Minner S, Quaas A.

Am J Pathol. 2014 Mar;184(3):609-17. doi: 10.1016/j.ajpath.2013.11.007. Epub 2013 Dec 28.

PMID:
24378408
9.

Loss of CDKN1B/p27Kip1 expression is associated with ERG fusion-negative prostate cancer, but is unrelated to patient prognosis.

Sirma H, Broemel M, Stumm L, Tsourlakis T, Steurer S, Tennstedt P, Salomon G, Michl U, Haese A, Simon R, Sauter G, Schlomm T, Minner S.

Oncol Lett. 2013 Nov;6(5):1245-1252. Epub 2013 Sep 4.

10.

Reduced CD147 expression is linked to ERG fusion-positive prostate cancers but lacks substantial impact on PSA recurrence in patients treated by radical prostatectomy.

Grupp K, Höhne TS, Prien K, Hube-Magg C, Tsourlakis MC, Sirma H, Pham T, Heinzer H, Graefen M, Michl U, Simon R, Wilczak W, Izbicki J, Sauter G, Minner S, Schlomm T, Steurer S.

Exp Mol Pathol. 2013 Oct;95(2):227-34. doi: 10.1016/j.yexmp.2013.08.002. Epub 2013 Aug 12.

PMID:
23948277
11.

High lysophosphatidylcholine acyltransferase 1 expression independently predicts high risk for biochemical recurrence in prostate cancers.

Grupp K, Sanader S, Sirma H, Simon R, Koop C, Prien K, Hube-Magg C, Salomon G, Graefen M, Heinzer H, Minner S, Izbicki JR, Sauter G, Schlomm T, Tsourlakis MC.

Mol Oncol. 2013 Dec;7(6):1001-11. doi: 10.1016/j.molonc.2013.07.009. Epub 2013 Jul 19.

12.

High nuclear karyopherin α 2 expression is a strong and independent predictor of biochemical recurrence in prostate cancer patients treated by radical prostatectomy.

Grupp K, Habermann M, Sirma H, Simon R, Steurer S, Hube-Magg C, Prien K, Burkhardt L, Jedrzejewska K, Salomon G, Heinzer H, Wilczak W, Kluth M, Izbicki JR, Sauter G, Minner S, Schlomm T, Tsourlakis MC.

Mod Pathol. 2014 Jan;27(1):96-106. doi: 10.1038/modpathol.2013.127. Epub 2013 Jul 26.

13.

SPINK1 expression is tightly linked to 6q15- and 5q21-deleted ERG-fusion negative prostate cancers but unrelated to PSA recurrence.

Grupp K, Diebel F, Sirma H, Simon R, Breitmeyer K, Steurer S, Hube-Magg C, Prien K, Pham T, Weigand P, Michl U, Heinzer H, Kluth M, Minner S, Tsourlakis MC, Izbicki JR, Sauter G, Schlomm T, Wilczak W.

Prostate. 2013 Nov;73(15):1690-8. doi: 10.1002/pros.22707. Epub 2013 Jul 10.

PMID:
23843146
14.

Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion-positive prostate cancers.

Krohn A, Seidel A, Burkhardt L, Bachmann F, Mader M, Grupp K, Eichenauer T, Becker A, Adam M, Graefen M, Huland H, Kurtz S, Steurer S, Tsourlakis MC, Minner S, Michl U, Schlomm T, Sauter G, Simon R, Sirma H.

J Pathol. 2013 Sep;231(1):130-41. doi: 10.1002/path.4223.

PMID:
23794398
15.

Overexpression of the chromatin remodeler death-domain-associated protein in prostate cancer is an independent predictor of early prostate-specific antigen recurrence.

Tsourlakis MC, Schoop M, Plass C, Huland H, Graefen M, Steuber T, Schlomm T, Simon R, Sauter G, Sirma H, Minner S.

Hum Pathol. 2013 Sep;44(9):1789-96. doi: 10.1016/j.humpath.2013.01.022. Epub 2013 May 2.

PMID:
23642739
16.

Strong expression of the neuronal transcription factor FOXP2 is linked to an increased risk of early PSA recurrence in ERG fusion-negative cancers.

Stumm L, Burkhardt L, Steurer S, Simon R, Adam M, Becker A, Sauter G, Minner S, Schlomm T, Sirma H, Michl U.

J Clin Pathol. 2013 Jul;66(7):563-8. doi: 10.1136/jclinpath-2012-201335. Epub 2013 Apr 4.

PMID:
23559350
17.

CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer.

Burkhardt L, Fuchs S, Krohn A, Masser S, Mader M, Kluth M, Bachmann F, Huland H, Steuber T, Graefen M, Schlomm T, Minner S, Sauter G, Sirma H, Simon R.

Cancer Res. 2013 May 1;73(9):2795-805. doi: 10.1158/0008-5472.CAN-12-1342. Epub 2013 Mar 14.

18.

Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer.

Weischenfeldt J, Simon R, Feuerbach L, Schlangen K, Weichenhan D, Minner S, Wuttig D, Warnatz HJ, Stehr H, Rausch T, Jäger N, Gu L, Bogatyrova O, Stütz AM, Claus R, Eils J, Eils R, Gerhäuser C, Huang PH, Hutter B, Kabbe R, Lawerenz C, Radomski S, Bartholomae CC, Fälth M, Gade S, Schmidt M, Amschler N, Haß T, Galal R, Gjoni J, Kuner R, Baer C, Masser S, von Kalle C, Zichner T, Benes V, Raeder B, Mader M, Amstislavskiy V, Avci M, Lehrach H, Parkhomchuk D, Sultan M, Burkhardt L, Graefen M, Huland H, Kluth M, Krohn A, Sirma H, Stumm L, Steurer S, Grupp K, Sültmann H, Sauter G, Plass C, Brors B, Yaspo ML, Korbel JO, Schlomm T.

Cancer Cell. 2013 Feb 11;23(2):159-70. doi: 10.1016/j.ccr.2013.01.002.

19.

Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions.

Kluth M, Hesse J, Heinl A, Krohn A, Steurer S, Sirma H, Simon R, Mayer PS, Schumacher U, Grupp K, Izbicki JR, Pantel K, Dikomey E, Korbel JO, Plass C, Sauter G, Schlomm T, Minner S.

Mod Pathol. 2013 Jul;26(7):975-83. doi: 10.1038/modpathol.2012.236. Epub 2013 Feb 1.

20.

High c-MET expression is frequent but not associated with early PSA recurrence in prostate cancer.

Jacobsen F, Ashtiani SN, Tennstedt P, Heinzer H, Simon R, Sauter G, Sirma H, Tsourlakis MC, Minner S, Schlomm T, Michl U.

Exp Ther Med. 2013 Jan;5(1):102-106. Epub 2012 Oct 25.

21.

Cysteine-rich secretory protein 3 overexpression is linked to a subset of PTEN-deleted ERG fusion-positive prostate cancers with early biochemical recurrence.

Grupp K, Kohl S, Sirma H, Simon R, Steurer S, Becker A, Adam M, Izbicki J, Sauter G, Minner S, Schlomm T, Tsourlakis MC.

Mod Pathol. 2013 May;26(5):733-42. doi: 10.1038/modpathol.2012.206. Epub 2012 Nov 30.

22.

Intratumoral heterogeneity of KRAS mutation is rare in non-small-cell lung cancer.

Alsdorf WH, Clauditz TS, Hoenig T, Quaas A, Sirma H, Koenig AM, Izbicki J, Sauter G, Marx AH, Grob TJ.

Exp Mol Pathol. 2013 Feb;94(1):155-9. doi: 10.1016/j.yexmp.2012.09.016. Epub 2012 Sep 27.

PMID:
23022742
23.

Loss of pSer2448-mTOR expression is linked to adverse prognosis and tumor progression in ERG-fusion-positive cancers.

Müller J, Ehlers A, Burkhardt L, Sirma H, Steuber T, Graefen M, Sauter G, Minner S, Simon R, Schlomm T, Michl U.

Int J Cancer. 2013 Mar 15;132(6):1333-40. doi: 10.1002/ijc.27768. Epub 2012 Aug 30.

24.

Selective induction of apoptosis by HMG-CoA reductase inhibitors in hepatoma cells and dependence on p53 expression.

Kah J, Wüstenberg A, Keller AD, Sirma H, Montalbano R, Ocker M, Volz T, Dandri M, Tiegs G, Sass G.

Oncol Rep. 2012 Sep;28(3):1077-83. doi: 10.3892/or.2012.1860. Epub 2012 Jun 12.

PMID:
22710979
25.

Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer.

Krohn A, Diedler T, Burkhardt L, Mayer PS, De Silva C, Meyer-Kornblum M, Kötschau D, Tennstedt P, Huang J, Gerhäuser C, Mader M, Kurtz S, Sirma H, Saad F, Steuber T, Graefen M, Plass C, Sauter G, Simon R, Minner S, Schlomm T.

Am J Pathol. 2012 Aug;181(2):401-12. doi: 10.1016/j.ajpath.2012.04.026. Epub 2012 Jun 13.

PMID:
22705054
26.

TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-β signaling.

Brase JC, Johannes M, Mannsperger H, Fälth M, Metzger J, Kacprzyk LA, Andrasiuk T, Gade S, Meister M, Sirma H, Sauter G, Simon R, Schlomm T, Beissbarth T, Korf U, Kuner R, Sültmann H.

BMC Cancer. 2011 Dec 5;11:507. doi: 10.1186/1471-2407-11-507.

27.

ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy.

Minner S, Enodien M, Sirma H, Luebke AM, Krohn A, Mayer PS, Simon R, Tennstedt P, Müller J, Scholz L, Brase JC, Liu AY, Schlüter H, Pantel K, Schumacher U, Bokemeyer C, Steuber T, Graefen M, Sauter G, Schlomm T.

Clin Cancer Res. 2011 Sep 15;17(18):5878-88. doi: 10.1158/1078-0432.CCR-11-1251. Epub 2011 Jul 26.

28.

Inhibition of experimental HCC growth in mice by use of the kinase inhibitor DMAT.

Sass G, Klinger N, Sirma H, Hashemolhosseini S, Hellerbrand C, Neureiter D, Wege H, Ocker M, Tiegs G.

Int J Oncol. 2011 Aug;39(2):433-42. doi: 10.3892/ijo.2011.1037. Epub 2011 May 10.

PMID:
21567083
29.

The promoter of human telomerase reverse transcriptase is activated during liver regeneration and hepatocyte proliferation.

Sirma H, Kumar M, Meena JK, Witt B, Weise JM, Lechel A, Ande S, Sakk V, Guguen-Guillouzo C, Zender L, Rudolph KL, Günes C.

Gastroenterology. 2011 Jul;141(1):326-37, 337.e1-3. doi: 10.1053/j.gastro.2011.03.047. Epub 2011 Mar 27.

PMID:
21447332
30.

PML isoforms I and II participate in PML-dependent restriction of HSV-1 replication.

Cuchet D, Sykes A, Nicolas A, Orr A, Murray J, Sirma H, Heeren J, Bartelt A, Everett RD.

J Cell Sci. 2011 Jan 15;124(Pt 2):280-91. doi: 10.1242/jcs.075390. Epub 2010 Dec 20.

31.

Functional p53 is required for effective execution of telomerase inhibition in BCR-ABL-positive CML cells.

Brassat U, Balabanov S, Bali D, Dierlamm J, Braig M, Hartmann U, Sirma H, Günes C, Wege H, Fehse B, Gontarewicz A, Dikomey E, Borgmann K, Brümmendorf TH.

Exp Hematol. 2011 Jan;39(1):66-76.e1-2. doi: 10.1016/j.exphem.2010.10.001. Epub 2010 Oct 30.

PMID:
20940029
32.

Is there Emergence of Clinical HBV Resistance Under Long-Term HBV Combination Therapy? A Challenging Case Report.

Schewe K, Noah C, Sirma H, Schmiedel S, van Lunzen J, Rockstroh JK, Schildgen O.

Viruses. 2010 Aug;2(8):1564-70. doi: 10.3390/v2081564. Epub 2010 Jul 29.

33.

SUMO modification of E1B-55K oncoprotein regulates isoform-specific binding to the tumour suppressor protein PML.

Wimmer P, Schreiner S, Everett RD, Sirma H, Groitl P, Dobner T.

Oncogene. 2010 Oct 7;29(40):5511-22. doi: 10.1038/onc.2010.284. Epub 2010 Jul 19.

PMID:
20639899
34.

Proteasome-dependent degradation of Daxx by the viral E1B-55K protein in human adenovirus-infected cells.

Schreiner S, Wimmer P, Sirma H, Everett RD, Blanchette P, Groitl P, Dobner T.

J Virol. 2010 Jul;84(14):7029-38. doi: 10.1128/JVI.00074-10. Epub 2010 May 19.

35.

Selection and counterselection of the rtI233V adefovir resistance mutation during antiviral therapy.

Schildgen O, Olotu C, Funk A, Zöllner B, Helm M, Rockstroh JK, Sirma H.

J Clin Microbiol. 2010 Feb;48(2):631-4. doi: 10.1128/JCM.01073-09. Epub 2009 Dec 9.

36.

Duck hepatitis B virus requires cholesterol for endosomal escape during virus entry.

Funk A, Mhamdi M, Hohenberg H, Heeren J, Reimer R, Lambert C, Prange R, Sirma H.

J Virol. 2008 Nov;82(21):10532-42. doi: 10.1128/JVI.00422-08. Epub 2008 Sep 3.

37.

Replication of ICP0-null mutant herpes simplex virus type 1 is restricted by both PML and Sp100.

Everett RD, Parada C, Gripon P, Sirma H, Orr A.

J Virol. 2008 Mar;82(6):2661-72. Epub 2007 Dec 26.

38.

Assembly and budding of a hepatitis B virus is mediated by a novel type of intracellular vesicles.

Mhamdi M, Funk A, Hohenberg H, Will H, Sirma H.

Hepatology. 2007 Jul;46(1):95-106.

PMID:
17567837
39.

Does pre-treatment with lamivudine prime for adefovir resistance of hepatitis B virus infection?

Sirma H, Funk A, Gerlich W, Schildgen O.

J Antimicrob Chemother. 2007 Aug;60(2):448-9. Epub 2007 Jun 7. No abstract available.

PMID:
17561492
40.

Strong and selective inhibitors of hepatitis B virus replication among novel N4-hydroxy- and 5-methyl-beta-L-deoxycytidine analogues.

Matthes E, Funk A, Krahn I, Gaertner K, von Janta-Lipinski M, Lin L, Will H, Sirma H.

Antimicrob Agents Chemother. 2007 Jul;51(7):2523-30. Epub 2007 Apr 2.

41.

Avian hepatitis B viruses: molecular and cellular biology, phylogenesis, and host tropism.

Funk A, Mhamdi M, Will H, Sirma H.

World J Gastroenterol. 2007 Jan 7;13(1):91-103. Review.

42.

pH-independent entry and sequential endosomal sorting are major determinants of hepadnaviral infection in primary hepatocytes.

Funk A, Mhamdi M, Hohenberg H, Will H, Sirma H.

Hepatology. 2006 Sep;44(3):685-93.

PMID:
16941679
43.

PML nuclear bodies are highly organised DNA-protein structures with a function in heterochromatin remodelling at the G2 phase.

Luciani JJ, Depetris D, Usson Y, Metzler-Guillemain C, Mignon-Ravix C, Mitchell MJ, Megarbane A, Sarda P, Sirma H, Moncla A, Feunteun J, Mattei MG.

J Cell Sci. 2006 Jun 15;119(Pt 12):2518-31. Epub 2006 May 30.

44.

Variant of hepatitis B virus with primary resistance to adefovir.

Schildgen O, Sirma H, Funk A, Olotu C, Wend UC, Hartmann H, Helm M, Rockstroh JK, Willems WR, Will H, Gerlich WH.

N Engl J Med. 2006 Apr 27;354(17):1807-12.

45.

Identification of a structural motif crucial for infectivity of hepatitis B viruses.

Stoeckl L, Funk A, Kopitzki A, Brandenburg B, Oess S, Will H, Sirma H, Hildt E.

Proc Natl Acad Sci U S A. 2006 Apr 25;103(17):6730-4. Epub 2006 Apr 17.

46.

Evidence from nature: interspecies spread of heron hepatitis B viruses.

Lin L, Prassolov A, Funk A, Quinn L, Hohenberg H, Frölich K, Newbold J, Ludwig A, Will H, Sirma H, Steinbach F.

J Gen Virol. 2005 May;86(Pt 5):1335-42.

PMID:
15831944
47.
48.

Itinerary of hepatitis B viruses: delineation of restriction points critical for infectious entry.

Funk A, Mhamdi M, Lin L, Will H, Sirma H.

J Virol. 2004 Aug;78(15):8289-300.

49.

Nuclear translocation of papillomavirus minor capsid protein L2 requires Hsc70.

Florin L, Becker KA, Sapp C, Lambert C, Sirma H, Müller M, Streeck RE, Sapp M.

J Virol. 2004 Jun;78(11):5546-53.

50.

Supplemental Content

Support Center